# An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

Source: https://onco.cc/trials/nct06560112/  
OnCo record `nct06560112` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cadonilimab, Ivonescimab in ovarian cancer, run by Akeso, now recruiting.

## Summary

An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer is a phase 2 interventional study registered as NCT06560112 by Akeso, with 172 participants planned, started 2024-11-12 and due to reach its primary completion in 2026-05-01. Interventions recorded: AK104, AK112, Chemotherapy. Conditions listed: Recurrent Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06560112
- Phase: 2
- Setting: An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer
- Sponsor: Akeso
- Enrolled: 172

## Sources

- ClinicalTrials.gov NCT06560112: https://clinicaltrials.gov/study/NCT06560112

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Cadonilimab](https://onco.cc/drugs/cadonilimab/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct06560112.json